AR087205A1 - Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas - Google Patents
Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanasInfo
- Publication number
- AR087205A1 AR087205A1 ARP120102578A ARP120102578A AR087205A1 AR 087205 A1 AR087205 A1 AR 087205A1 AR P120102578 A ARP120102578 A AR P120102578A AR P120102578 A ARP120102578 A AR P120102578A AR 087205 A1 AR087205 A1 AR 087205A1
- Authority
- AR
- Argentina
- Prior art keywords
- pirfenidone
- release tablets
- pharmaceutical composition
- regression
- manufacture
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 206010019668 Hepatic fibrosis Diseases 0.000 title abstract 2
- 206010062575 Muscle contracture Diseases 0.000 title abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
- 208000006111 contracture Diseases 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 abstract 7
- 229960003073 pirfenidone Drugs 0.000 abstract 7
- 238000013265 extended release Methods 0.000 abstract 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 4
- 239000003826 tablet Substances 0.000 abstract 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- 210000000481 breast Anatomy 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 230000003510 anti-fibrotic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000377 silicon dioxide Substances 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011007675A MX2011007675A (es) | 2011-07-19 | 2011-07-19 | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087205A1 true AR087205A1 (es) | 2014-02-26 |
Family
ID=46940567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102578A AR087205A1 (es) | 2011-07-19 | 2012-07-16 | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas |
Country Status (34)
Country | Link |
---|---|
US (6) | US9408836B2 (de) |
EP (2) | EP2735306A1 (de) |
JP (1) | JP6034380B2 (de) |
KR (2) | KR20160074016A (de) |
CN (2) | CN103957892A (de) |
AR (1) | AR087205A1 (de) |
AU (1) | AU2012284627B2 (de) |
BR (1) | BR112014001297B1 (de) |
CA (1) | CA2842654C (de) |
CL (1) | CL2014000131A1 (de) |
CO (1) | CO6970587A2 (de) |
CR (1) | CR20140019A (de) |
CY (2) | CY2200005T2 (de) |
DE (1) | DE15161929T1 (de) |
DK (1) | DK2907506T3 (de) |
DO (1) | DOP2014000010A (de) |
EC (1) | ECSP14013160A (de) |
ES (1) | ES2550227T3 (de) |
HK (1) | HK1208172A1 (de) |
HR (1) | HRP20180183T1 (de) |
HU (1) | HUE036511T2 (de) |
LT (1) | LT2907506T (de) |
MX (1) | MX2011007675A (de) |
NO (1) | NO2907506T3 (de) |
PE (1) | PE20141684A1 (de) |
PL (1) | PL2907506T3 (de) |
PT (1) | PT2907506T (de) |
RS (1) | RS56858B1 (de) |
RU (1) | RU2682177C2 (de) |
SI (1) | SI2907506T1 (de) |
UA (1) | UA114181C2 (de) |
UY (1) | UY34190A (de) |
WO (1) | WO2013012307A1 (de) |
ZA (1) | ZA201400386B (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
JP6525437B2 (ja) | 2014-04-02 | 2019-06-05 | インターミューン, インコーポレイテッド | 抗線維性ピリジノン |
CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
CN105997302A (zh) * | 2016-07-18 | 2016-10-12 | 青岛三帝生物科技有限公司 | 基于3d打印的防包膜挛缩乳房假体制作方法和乳房假体 |
MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
KR20180100869A (ko) * | 2017-03-02 | 2018-09-12 | 영진약품 주식회사 | 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법 |
CN107080741A (zh) * | 2017-04-28 | 2017-08-22 | 北京工业大学 | 吡非尼酮缓释制剂及制备方法 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
US10980747B2 (en) * | 2017-11-27 | 2021-04-20 | Shin-Etsu Chemical Co., Ltd. | Composition for solid preparation, solid preparation, and method for producing the same |
EP3511001B1 (de) | 2018-01-12 | 2021-09-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidonhaltige tablette und kapselformulierung |
KR20210003197A (ko) | 2018-04-23 | 2021-01-11 | 티엘씨 바이오파머슈티컬즈 인코포레이티드 | 폐 질환 치료에 사용하기 위한 흡입 가능한 리포솜 서방형 조성물 |
WO2020115774A1 (en) | 2018-12-06 | 2020-06-11 | Cipla Limited | High drug load extended release formulations |
KR102199415B1 (ko) * | 2019-02-18 | 2021-01-06 | 충북대학교 산학협력단 | 중합체 및 채널링제를 포함하는 피르페니돈 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제 |
MX2022012986A (es) * | 2020-04-14 | 2023-03-21 | Excalibur Pharmaceuticals Inc | Pirfenidona para el tratamiento del coronavirus. |
JP7490813B2 (ja) * | 2020-04-22 | 2024-05-27 | ユンジン ファーム.カンパニー、リミテッド | 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US3839346A (en) | 1972-12-18 | 1974-10-01 | Affiliated Med Res | N-substituted pyridone and general method for preparing pyridones |
DE2362958C2 (de) | 1972-12-18 | 1984-06-14 | Affiliated Medical Research Inc., Princeton, N.J. | Pharmazeutische Zusammensetzung zur Linderung von Entzündungen, Fieber oder Schmerzen bei Säugetieren oder zur Senkung des Harnsäurespiegels im Blutserum |
CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
US4105782A (en) | 1975-03-07 | 1978-08-08 | Yu Ruey J | Treatment of acne and dandruff |
JPS51128438A (en) | 1975-04-26 | 1976-11-09 | Yamanouchi Pharmaceut Co Ltd | An antibacterial drug against fish diseases |
SE430609B (sv) | 1976-12-21 | 1983-11-28 | Sca Development Ab | Sett att ur cellulosaderivat framstella absorberande material |
US4376118A (en) | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
SU1719047A1 (ru) * | 1989-11-09 | 1992-03-15 | Воронежский инженерно-строительный институт | Вибрационный гранул тор |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
ES2082723B1 (es) * | 1994-07-20 | 1996-10-01 | Lilly Sa | Formulacion farmaceutica de fluoxetina en forma dispersable. |
PL186795B1 (pl) | 1995-12-21 | 2004-02-27 | Pfizer | Preparat farmaceutyczny zawierający danofloksacynę |
US5958420A (en) | 1997-03-13 | 1999-09-28 | Nortrade Medical, Inc. | Treatment of burns, cuts, and abrasions of the skin |
US6365131B1 (en) | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
ES2221365T3 (es) | 1998-03-17 | 2004-12-16 | Solomon B. Margolin | Composiciones y metodos topicos antisepticos. |
GB9810949D0 (en) | 1998-05-22 | 1998-07-22 | Hewlett Healthcare Limited | Formulation |
US6492395B1 (en) | 1998-09-18 | 2002-12-10 | Mepha Ag | Topical formulation of alkyl-, phenyl-pyridone |
US6277407B1 (en) * | 1998-11-10 | 2001-08-21 | Frederick S. Marius | Apparatus and method for tablet fabrication |
HUP0104606A3 (en) * | 1998-12-18 | 2003-01-28 | Basf Ag | A pharmaceutical mixture comprising a profen |
IN191090B (de) | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
TW200501952A (en) | 2003-02-21 | 2005-01-16 | Shionogi & Co | Pirfenidone gel formulations |
US8222299B2 (en) | 2003-05-23 | 2012-07-17 | Allium Vitalis Incorporated | Organosulfur prodrugs for the prevention and treatment of infectious diseases |
WO2005000227A2 (en) | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
US8168228B2 (en) * | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
US20060051339A1 (en) | 2004-09-08 | 2006-03-09 | Sivak Hannah N | Composition for treatment of oily skin and acne prevention and methods of making and using same |
US20060115503A1 (en) | 2004-11-30 | 2006-06-01 | Goyal Muna C | Composition, system and method for treatment of skin |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
WO2007068086A1 (en) | 2005-12-05 | 2007-06-21 | Bioartificial Gel Technologies Inc. | Emulsion-containing medical articles |
CA2645940A1 (en) * | 2006-03-21 | 2007-09-27 | Teva Pharmaceutical Industries Ltd. | Controlled release formulation of tolterodine |
JP5213852B2 (ja) * | 2006-06-15 | 2013-06-19 | シャンハイ ゲノミックス インク | 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用 |
EP3053580B1 (de) * | 2006-12-18 | 2021-06-30 | InterMune, Inc. | Verfahren zur bereitstellung einer pirfenidontherapie an einem patienten |
JP2010520194A (ja) | 2007-03-02 | 2010-06-10 | ミロン、タリア | 抗癌剤としてのメルカプトプリン誘導体 |
MX2007006347A (es) * | 2007-05-29 | 2009-02-18 | Cell Therapy And Technology S | Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma. |
US8383823B2 (en) * | 2007-06-20 | 2013-02-26 | Auspex Pharmaceuticals | Substituted N-aryl pyridinones |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
CN101244045B (zh) * | 2007-12-21 | 2010-06-30 | 东华大学 | 一种零级给药口服控释片剂及其制备方法 |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
MX352342B (es) | 2013-07-12 | 2017-11-22 | Moleculas Naturales S A De C V Star | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado, el complejo obtenido y sus usos. |
MX364040B (es) | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
-
2011
- 2011-07-19 MX MX2011007675A patent/MX2011007675A/es active IP Right Grant
-
2012
- 2012-07-09 UY UY0001034190A patent/UY34190A/es active IP Right Grant
- 2012-07-13 AU AU2012284627A patent/AU2012284627B2/en active Active
- 2012-07-13 HU HUE15161929A patent/HUE036511T2/hu unknown
- 2012-07-13 KR KR1020167015898A patent/KR20160074016A/ko not_active Application Discontinuation
- 2012-07-13 US US14/233,600 patent/US9408836B2/en active Active
- 2012-07-13 JP JP2014521581A patent/JP6034380B2/ja active Active
- 2012-07-13 CN CN201280045648.XA patent/CN103957892A/zh active Pending
- 2012-07-13 CN CN202011071995.2A patent/CN112386579A/zh active Pending
- 2012-07-13 LT LTEP15161929.3T patent/LT2907506T/lt unknown
- 2012-07-13 DE DE15161929.3T patent/DE15161929T1/de active Pending
- 2012-07-13 PT PT15161929T patent/PT2907506T/pt unknown
- 2012-07-13 EP EP12766487.8A patent/EP2735306A1/de not_active Withdrawn
- 2012-07-13 ES ES15161929.3T patent/ES2550227T3/es active Active
- 2012-07-13 KR KR1020147002065A patent/KR101632332B1/ko active IP Right Grant
- 2012-07-13 RS RS20180168A patent/RS56858B1/sr unknown
- 2012-07-13 PE PE2014000097A patent/PE20141684A1/es active IP Right Grant
- 2012-07-13 BR BR112014001297-0A patent/BR112014001297B1/pt active IP Right Grant
- 2012-07-13 RU RU2014101231A patent/RU2682177C2/ru not_active Application Discontinuation
- 2012-07-13 SI SI201231198T patent/SI2907506T1/en unknown
- 2012-07-13 WO PCT/MX2012/000067 patent/WO2013012307A1/es active Application Filing
- 2012-07-13 UA UAA201401623A patent/UA114181C2/uk unknown
- 2012-07-13 DK DK15161929.3T patent/DK2907506T3/en active
- 2012-07-13 PL PL15161929T patent/PL2907506T3/pl unknown
- 2012-07-13 CA CA2842654A patent/CA2842654C/en active Active
- 2012-07-13 NO NO15161929A patent/NO2907506T3/no unknown
- 2012-07-13 EP EP15161929.3A patent/EP2907506B1/de active Active
- 2012-07-16 AR ARP120102578A patent/AR087205A1/es not_active Application Discontinuation
-
2014
- 2014-01-16 CR CR20140019A patent/CR20140019A/es unknown
- 2014-01-17 CO CO14008053A patent/CO6970587A2/es unknown
- 2014-01-17 CL CL2014000131A patent/CL2014000131A1/es unknown
- 2014-01-17 ZA ZA2014/00386A patent/ZA201400386B/en unknown
- 2014-01-20 DO DO2014000010A patent/DOP2014000010A/es unknown
- 2014-01-21 EC ECSP14013160 patent/ECSP14013160A/es unknown
-
2015
- 2015-09-10 HK HK15108824.8A patent/HK1208172A1/xx unknown
- 2015-12-16 CY CY20152200005T patent/CY2200005T2/el unknown
-
2016
- 2016-06-09 US US15/177,760 patent/US9962374B2/en active Active
-
2017
- 2017-12-05 US US15/831,650 patent/US10383862B2/en active Active
-
2018
- 2018-01-31 HR HRP20180183TT patent/HRP20180183T1/hr unknown
- 2018-02-05 CY CY20181100141T patent/CY1119886T1/el unknown
-
2019
- 2019-07-02 US US16/460,407 patent/US11040030B2/en active Active
- 2019-08-19 US US16/544,643 patent/US11052074B2/en active Active
-
2021
- 2021-06-17 US US17/351,151 patent/US20210386724A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087205A1 (es) | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas | |
SI3079671T1 (en) | Oral disintegration solid dosage form containing an esterol component | |
EA201100313A1 (ru) | Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом | |
RU2011138490A (ru) | Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон | |
MX363495B (es) | Proceso de manufacturacion de una forma de dosificacion multifasica de rapida disolucion liofilizada. | |
AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
KR101612197B1 (ko) | 부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법 | |
RU2014129508A (ru) | Новая комбинация | |
RU2008113588A (ru) | 2-этил-6-метил-3-гидроксипиридинийгидроксибутандиоат, обладающий противоишемической, церебропротекторной, нейротропной и липидрегулируемой активностями, фармацевтические композиции и лекарственное средство | |
DOP2002000389A (es) | Metodo para fabricar una composición farmaceutica de dosis baja que tiene una distribución y potencia del fármaco uniforme | |
BRPI0615195A8 (pt) | preparação farmacêutica, embalagem, e, métodos para tratar doença gastrintestinal, para fabricar uma cápsula e para testar dissolução de cápsulas de balsalazida. | |
EA200800075A1 (ru) | Схема дозирования для празугреля | |
CN106214653A (zh) | 一种沙芬酰胺缓释片及其制备方法 | |
WO2013169218A1 (en) | Pharmaceutical compositions of s-etodolac | |
RU2010154623A (ru) | Производные 1-аминоалкилциклогексана для лечения расстройств сна | |
RU2013127794A (ru) | Фармацевтическая комбинация и композиция для лечения ожирения и ее применение | |
RU2570374C2 (ru) | Твердая лекарственная форма препарата седативного и спазмолитического действия | |
TH147179A (th) | กระบวนการสำหรับการเตรียมขององค์ประกอบทางเภสัชกรรมที่บรรจุเพียร์เฟนิโดนในรูปยาเม็ดชนิดปลดปล่อยเนิ่นนาน และการใช้ของสิ่งนั้นในการทุเลาของ ภาวะไตวายเรื้อรัง, ภาวะพังผืดหดรัดของเต้านม, และ ภาวะพังผืดที่ตับของมุนษย์ | |
RU2014125701A (ru) | Фармацевтическая композиция для профилактики или лечения гипертриглицеридемии или вызванных гипертриглицеридемией заболеваний | |
EA202192083A1 (ru) | Фармацевтическая композиция на основе макозинона для лечения туберкулеза, включая его формы с множественной и широкой лекарственной устойчивостью | |
ES2524865T1 (es) | Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata | |
EA201171014A1 (ru) | Средство противовирусной и иммуностимулирующей активности, способ получения средства противовирусной и иммуностимулирующей активности, способ профилактики и лечения инфекционных болезней | |
BR112021024054A2 (pt) | Composições farmacêuticas de combinação de dose fixa de liberação imediata, seus métodos e usos. | |
MX2017016145A (es) | Composiciones farmaceuticas para la administracion oral de una dosis unitaria de un agente hipoglucemiante y una dosis unitaria baja de un agente anorexico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |